Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

ClinicalTrials.gov ID: NCT04537884

Public ClinicalTrials.gov record NCT04537884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.

Study identification

NCT ID
NCT04537884
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Unity Biotechnology, Inc.
Industry
Enrollment
19 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 8, 2020 (Actual)
Primary completion
Jan 25, 2022 (Actual)
Completion
Jan 25, 2022 (Actual)
Last update posted
Mar 10, 2022

2020 – 2022

United States locations

U.S. sites
8
U.S. states
4
U.S. cities
8
Facility City State ZIP Site status
Retina-Vitreous Associates Medical Group Beverly Hills California 90211 —
Salehi Retina Institute Huntington Beach California 92647 —
MedEye Associates Miami Florida 33143 —
Sarasota Retina Institute Sarasota Florida 34239 —
Center for Retina and Macular Disease Winter Haven Florida 33880 —
MidWest Eye Institute Indianapolis Indiana 46290 —
Houston Eye Associates Houston Texas 77025 —
Medical Center Ophthalmology Associates San Antonio Texas 78240 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04537884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2022 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04537884 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →